The findings in the individuals studied here do not indicate any good thing about continuing neuroleptic therapies in old patients with dementia. However, the numbers of patients studied in this trial can be small. More studies are urgently needed to improve the management of these patients. Citation: Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics . PLoS Med 5: e76.. A randomised, blinded, placebo-controlled trial in dementia individuals stopping or continuing neuroleptics Results of a randomised trial published in PLoS Medicine show no benefit in cognitive or neuropsychiatric outcomes from continuing neuroleptic drugs in patients with Alzheimer’s disease.As analysis of data from the to begin the four trials begins, the company expects that full data gathering and evaluation will take a period of weeks before best line results are announced some time in June 2010. The ongoing company expects to lift the quiet period following disclosure of Phase 3 results.
AHF shares The Lancet’s concerns over use of Gilead’s Truvada as HIV prevention pill Today AIDS Healthcare Foundation commented on an editorial published in the September 2011 problem of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment medication Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis , agreeing with the publication’s open public health concerns.